Travere Therapeutics CFO Cline Christopher R. sold 642 shares at $66.37 each on September 2, 2026. Investors can use the transaction and his resulting ownership of 118,016 shares to track the executive’s disclosed position in the company.
Key Highlights
- The transaction occurred on September 2, 2026.
- Cline Christopher R. held 118,016 Travere Therapeutics shares after the sale.
- The transaction record identifies Cline as Travere Therapeutics’ chief financial officer.
Travere Therapeutics, Inc. (NASDAQ: TVTX) saw Chief Financial Officer Cline Christopher R. sell 642 shares at $66.37 per share. The transaction took place on September 2, 2026. Cline’s post-transaction ownership stood at 118,016 shares.
Cline’s Post-Sale Travere Position
His remaining position was stated as 118,016 shares after the sale. The transaction involved 642 shares at $66.37 per share. The disclosed ownership figure reflects the executive’s position following that transaction.
FAQs
Q: How many Travere Therapeutics shares did CFO Cline sell?
A: Cline Christopher R. Travere Therapeutics’ chief financial officer, sold 642 shares at $66.37 per share on September 2, 2026. The filing identifies the transaction as a Form 4 sale.
Q: How many Travere Therapeutics shares did Cline own after the sale?
A: After the transaction, Cline Christopher R. owned 118,016 Travere Therapeutics shares. This is the post-transaction ownership position reported in the filing.
Q: When did the Travere Therapeutics CFO share sale occur?
A: The Travere Therapeutics CFO share sale occurred on September 2, 2026. The filing reports that Cline Christopher R. sold 642 shares at $66.37 per share in that transaction.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.